P16抑癌基因在肾癌组织中的表达及临床意义

Suppressor gene P16 expression in renal cell carcinoma

为了探讨Ｐ１６抑癌基因与肾癌生物学行为的关系，采用免疫组化法检测了４５例肾癌组织和２５例癌旁肾组织中Ｐ１６基因的表达。结果：癌旁肾组织Ｐ１６阳性率（８０．０％）显著高于肾癌组织（５１．１％）。Ｐ１６阳性率在Ⅰ、Ⅱ和Ⅲ级肿瘤中分别为７８．６％、４７．４％和２５．０％（Ｐ＜０．０５）；在Ⅰ、Ⅱ和Ⅲ～Ⅳ期肿瘤中分别为６８．４％、５３．３％和１８．２％（Ｐ＜０．０５），显示Ｐ１６表达阳性率随肾癌病理分级、临床分期的上升而降低。Ｐ１６阳性与阴性表达组间３、５年生存率均存在显著性差异。提示抑癌基因Ｐ１６在防止肾癌的发生和发展中起着重要作用，可作为肾癌生物学行为及预后评估的参考指标。

Expression of suppressor gene P16 was investigated in 45 cases of renal cell carcinoma(RCC) and in 25 kidney tissue adjacent to nonneoplastic lesions.The result showed that the positive rate of P16 was higher in nonneoplasm tissue (80.0%) than in tumor tissue(51.1%).The P16 positive rate in gradeⅠ,Ⅱand Ⅲ tumors was 78.6%,47.4% and 25.0%( P <0.05)respectively and in stage Ⅰ,Ⅱ and Ⅲ～Ⅳ tumors being 68.4%,53.3% and 18.2%( P <0.05),the worse the grading and staging,the lower the presence of P16.There was a significant difference between P16 positive and negative cases in survival rate.The result suggested that P16 played an important role in suppressing the genesis and the development of RCC and could be used as a predictor of malignant potential and prognosis.